Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Receivables - Other of $807945.0 for Q1 2026, up 27683.53% year-over-year from N/an in Q1 2025, and up 65.44% quarter-over-quarter from $488372.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Receivables - Other for 7 consecutive years, with $807945.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other rose 27683.53% year-over-year to $807945.0; the TTM figure through Mar 2026 stood at $807945.0 (up 27683.53% YoY), while the FY2024 annual figure was $96154.0, down 76.89% from the prior year.
- Receivables - Other improved to $807945.0 in Q1 2026 per NEUP's latest filing, from $488372.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $4.8 million in Q2 2022 and bottomed at $592.17 in Q2 2023.
- Historically, Receivables - Other has averaged $701503.0 across 5 years, with a median of $96154.0 in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Other slumped 99.99% — and 2026, when it soared 27683.53%.
- Neuphoria Therapeutics' Receivables - Other stood at $4.8 million in 2022, then plunged by 99.99% to $592.17 in 2023, then soared by 241.29% to $2021.0 in 2024, then surged by 24064.87% to $488372.0 in 2025, then surged by 65.44% to $807945.0 in 2026.
- Business Quant data shows NEUP's Receivables - Other at $807945.0 in Q1 2026, $488372.0 in Q4 2025, and $1758.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 807,945.00 |
| Mar 31, 2026 | 807,945.00 |
| Dec 31, 2025 | 488,372.00 |
| Dec 31, 2025 | 488,372.00 |
| Sep 30, 2025 | 1,758.00 |
| Sep 30, 2025 | 1,758.00 |
| Mar 31, 2025 | 2,908.00 |
| Mar 31, 2025 | 2,908.00 |
| Dec 31, 2024 | 2,021.00 |
| Dec 31, 2024 | 2,021.00 |
| Sep 30, 2024 | 100,625.00 |
| Sep 30, 2024 | 100,625.00 |
| Jun 30, 2024 | 96,154.00 |
| Jun 30, 2024 | 96,154.00 |
| Jun 30, 2023 | 592.17 |
| Jun 30, 2023 | 592.17 |
| Jun 30, 2022 | 4.81 Mn |
| Jun 30, 2022 | 4.81 Mn |
| Jun 30, 2021 | 714,667.38 |
| Jun 30, 2021 | 714,667.38 |